This new structural variant complex shows anti-tumor activity on chronic myeloid leukemia by targeting the IL-8, survivin, and induces apoptosis through DNA fragmentation, but not against normal cells. Here, CXCL8 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.